research S90 Urethral PSA production after radical prostatectomy
After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.
Search
for
Sort by
Research
360-390 / 1000+ results 
research IMPACT OF LOW DOSE FINASTERIDE FOR THE TREATMENT OF ANDROGENIC ALOPECIA ON SERUM PROSTATE SPECIFIC ANTIGEN (PSA) LEVELS IN MEN PARTICIPATED IN POPULATION-BASED SCREENING FOR PROSTATE CANCER
Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.
research Association between PSA and leptin, adiponectin, HbA1c, or C-peptide among African-American and Caucasian men
Higher C-peptide levels in African-American men and higher HbA1c levels in Caucasian men are linked to lower PSA levels.
research Are PSA adjustments necessary for prostate cancer screening in men taking finasteride for hair loss?
Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.
research Finasteride reduces serum PSA to a similar extent at 1 mg and 5 mg daily doses
Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.
research Effect of Low-Dose Finasteride on Serum PSA Concentrations
Low-dose finasteride lowers PSA levels, which can make prostate cancer harder to detect.
research Impact of baseline PSA level on quality of life measures of general health and sexual satisfaction/drive in men with BPH treated with finasteride or placebo
Baseline PSA levels affect general health and sexual satisfaction in men with BPH treated with finasteride or placebo.
research 1450 THE TRUE BENEFIT OF PSA-SCREENING: MODELING THE IMPACT OF TRIAL SETTING AND PROTOCOL ON MORTALITY
PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.
research PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY
Finasteride reduces PSA levels by around 40-50% in BPH patients.
research PSA concentration change in men taking low dose finasteride and dutasteride for male androgenetic alopecia
research The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy
% free PSA and urinary markers help better identify prostate cancer.
research Επικύρωση της χρησιμότητας των νεότερων παραμέτρων του PSA ορού για την ανίχνευση του καρκίνου του προστάτη
Higher PSA levels can indicate prostate cancer, but there's overlap with non-cancerous conditions.
research Efeitos do uso da finasterida sobre o volume prostático e dosagem sérica do PSA em pacientes jovens
Finasteride reduces prostate size and PSA levels in young patients.
research Effects of the use of finasteride on prostate volume and serum PSA in young patients
Finasteride reduces prostate size and PSA levels in young men with hair loss.
research UP-02.010 Urinary PSA: Marker of Benign Prostatic Hyperplasia?
Urinary PSA could be an early marker for enlarged prostate.
research Modelling of the composition of emulsion medicines and cosmetics stabilized by a biocomplex of surfactant substances based on rhamnolipids Pseudomonas sp. PS-17
A semi-automated system can effectively help choose emulsion ingredients, simplifying the creation of medicinal and cosmetic products.
research FINASTERIDE AND PSA
research 42134 Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-naïve Patients With Psoriatic Arthritis (PsA)
Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.
research Urinary Retention in Patients with BPH Treated with Finasteride or Placebo over 4 Years
Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.
research Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial
Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.
research Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate
Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
research Acute urinary retention: risks and management.
Older men with severe symptoms and larger prostates should focus on prevention, using finasteride and alpha-blockers to manage acute urinary retention.
research 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review
5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
research Finasteride-its impact on sexual function and prostate cancer
Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.
research Dutasteride for the treatment of benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
research Primary Scarring Alopecia: Clinical-Pathological Review of 72 Cases and Review of the Literature
The conclusion is that primary scarring alopecia is a complex condition that requires early and accurate diagnosis for effective treatment.
research Relationship of Early-Onset Baldness to Prostate Cancer in African-American Men
Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.
research Corn silk extract improves benign prostatic hyperplasia in experimental rat model
Corn silk extract helps reduce prostate enlargement symptoms.
research Medikamentöse Therapie des benignen Prostatasyndroms
Combining medications is more effective for treating benign prostatic syndrome symptoms.
research Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.